Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking a double dose of Wegovy is not recommended and could be harmful. The licensed dosing schedule sets specific amounts at each stage of treatment for a reason: the titration steps that guide you from 0.25 mg up to the maintenance dose are designed to manage tolerability, not slow down results. If you have missed a dose or are tempted to take two in one week, the answer from both NHS guidance on semaglutide and the medicine's licensed prescribing information is clear: take the next dose at the usual time and skip the missed one if your next scheduled day is within two days. Doubling up is not a shortcut. It raises the likelihood of serious side effects and does not improve the medicine's long-term effectiveness.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors in the gut and brain, reducing appetite, slowing the rate at which the stomach empties and influencing blood-sugar regulation. Its biological half-life is around seven days, which is exactly why once-weekly dosing works: the drug accumulates steadily in the body and reaches a stable level over several weeks of consistent use. That pharmacokinetic profile is also why taking a double dose of Wegovy does not produce twice the benefit. You are not topping up an empty tank; you are flooding a system that already holds last week's dose. The result is a sharp spike in plasma concentration, not a therapeutic boost. In the STEP 1 trial published in the New England Journal of Medicine, the 15% average weight loss achieved with semaglutide 2.4 mg came from sustained, titrated dosing over 68 weeks, steady pharmacology, not surges. The titration ladder (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) was not designed to slow patients down; each rung exists because the gut needs time to adapt. Jumping doses, let alone doubling a semaglutide dose, removes that adaptation window. For a fuller picture of how the standard schedule is structured, the Wegovy doses guide explains what each stage involves and why the spacing matters.
Gastrointestinal side effects are the most common reason people struggle with Wegovy, particularly at the point of a dose increase. Nausea, vomiting, diarrhoea and stomach cramps typically peak in the first day or two after an injection and then ease. A double dose compresses two weeks of exposure into a single day, the concentration spike is abrupt, and the gut does not have time to adjust. Vomiting can become severe enough to cause meaningful dehydration, which in turn puts pressure on the kidneys. More seriously, the MHRA's Drug Safety Update of January 2026 specifically flagged acute pancreatitis as a known but infrequent risk with GLP-1 medicines: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. That risk profile is dose-related; taking more than prescribed raises exposure to it. Beyond the immediate physical effects, there is a practical concern: if you vomit shortly after injecting, you cannot simply re-dose, and managing that situation without clinical guidance is difficult. If you are weighing up the implications of taking two doses, the detail on what happens if you take a double dose of Wegovy covers the clinical picture in full. The short version is that the risks are real and the benefits are not.
The practical missed-dose instruction in Wegovy's prescribing information is straightforward: if you miss a dose and more than five days remain before your next scheduled injection, take it as soon as you remember. If fewer than five days remain before the next scheduled dose, skip the missed one and carry on with your usual day. Do not take two doses to compensate. That five-day window reflects the drug's half-life; enough semaglutide is still active in your system that a brief gap does not reset your progress. People sometimes assume that missing a dose sets them back weeks. It does not. Consistency across months matters far more than any single week. If you find yourself regularly forgetting injections, the solution is a routine adjustment rather than dose stacking. Some people keep their pen in the same spot in the fridge door every week and set a phone reminder for the same morning. Small, deliberate habits make more difference than trying to recover a missed dose. If missed doses are becoming a pattern, or if you are thinking about whether a different formulation of Wegovy might suit you better, that is a conversation worth having with your prescriber. Questions about your own schedule, including whether switching from another treatment affects your starting point, are covered in our FAQs and by our clinical team. For context on how Wegovy sits relative to other weight-management options, our treatment overview is a good starting point. Cost questions that sometimes drive people to consider skipping or doubling doses are addressed honestly on the Wegovy cost page. If you have questions about your own treatment or are considering starting, speaking to our prescribers is the right next step, no pressure, just a clinical review of your situation by a real person.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.